Repository logo
 

Characterising the disintegration properties of tablets in opaque media using texture analysis.


Change log

Authors

Scheuerle, Rebekah L 
Gerrard, Stephen E 
Kendall, Richard A 
Tuleu, Catherine 
Slater, Nigel KH 

Abstract

Tablet disintegration characterisation is used in pharmaceutical research, development, and quality control. Standard methods used to characterise tablet disintegration are often dependent on visual observation in measurement of disintegration times. This presents a challenge for disintegration studies of tablets in opaque, physiologically relevant media that could be useful for tablet formulation optimisation. This study has explored an application of texture analysis disintegration testing, a non-visual, quantitative means of determining tablet disintegration end point, by analysing the disintegration behaviour of two tablet formulations in opaque media. In this study, the disintegration behaviour of one tablet formulation manufactured in-house, and Sybedia Flashtab placebo tablets in water, bovine, and human milk were characterised. A novel method is presented to characterise the disintegration process and to quantify the disintegration end points of the tablets in various media using load data generated by a texture analyser probe. The disintegration times in the different media were found to be statistically different (P<0.0001) from one another for both tablet formulations using one-way ANOVA. Using the Tukey post-hoc test, the Sybedia Flashtab placebo tablets were found not to have statistically significant disintegration times from each other in human versus bovine milk (adjusted P value 0.1685).

Description

Keywords

Breast milk, Infant drug delivery, NSDS, Nipple shield delivery system, Rapidly disintegrating tablet, Texture analysis, Animals, Female, Humans, Milk, Milk, Human, Solubility, Tablets, Technology, Pharmaceutical, Water

Journal Title

Int J Pharm

Conference Name

Journal ISSN

0378-5173
1873-3476

Volume Title

486

Publisher

Elsevier BV
Sponsorship
This work was made possible through the generous support of the Saving Lives at Birth partners: the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada and the UK Department for International Development (DFID).